Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy source : Investors.biomarin.com save search
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-06-29 (Crawled : 19:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 1.2%
H: 1.97%
C: -3.69%
drug food therapy
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
Published: 2023-06-22 (Crawled : 12:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
international program trial therapy
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
Published: 2022-10-12 (Crawled : 21:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -1.7%
H: 3.35%
C: 2.24%
fda application license therapy
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
Published: 2022-09-29 (Crawled : 20:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.08%
H: 2.07%
C: -0.26%
fda application license therapy
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Published: 2022-09-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.26%
H: 1.82%
C: 1.69%
report therapy
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
Published: 2022-05-31 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 1.91%
H: 0.01%
C: -6.6%
ongoing therapy phase 1
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
Published: 2022-03-17 (Crawled : 12:30) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 1.26%
H: 1.69%
C: -0.02%
gene therapy trial one therapy results phase 3
BioMarin Provides Updates on Progress in Gene Therapy Programs
Published: 2022-02-17 (Crawled : 22:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
gene therapy program therapy
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
Published: 2021-12-16 (Crawled : 22:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.31%
H: 5.57%
C: 3.78%
cardio therapeutics disease gene therapies cardiovascular collaboration gene therapy therapy
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
Published: 2021-09-06 (Crawled : 06:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
| Email alert
Add to watchlist
fda pre-clinical phase 1 gene therapy therapy gene therapies preclinical clinical hold
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A
Published: 2021-05-19 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -1.13%
H: 0.38%
C: -0.48%
ongoing phase 1 gene therapy therapy phase 3 gene therapies
Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases
Published: 2021-04-28 (Crawled : 13:00) - investors.biomarin.com
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.82%
C: 0.57%
disease gene therapies therapy gene therapy rare train
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.